

October 28, 2021

VIA SEDAR

British Columbia Securities Commission
Ontario Securities Commission
Alberta Securities Commission
The Manitoba Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
Autorité des marchés financiers
Office of the Superintendent of Securities, Newfoundland and Labrador
Financial and Consumer Services Commission, New Brunswick
Nova Scotia Securities Commission
Office of the Superintendent of Securities, Prince Edward Island
Office of the Superintendent of Securities, Northwest Territories
Office of the Superintendent of Securities, Nunavut
Office of the Yukon Superintendent of Securities

Dear Sirs/Mesdames:

**Re: PsyBio Therapeutics Corp. (the “Company”) –
 Final Short Form Base Shelf Prospectus dated October 28, 2021**

We refer to the final short form base shelf prospectus of the Company dated October 28, 2021 (the “**Prospectus**”) relating to the qualification for distribution of subordinate voting shares, multiple voting shares, warrants, options, subscription receipts, debt securities and units of the Company.

We hereby consent to the reference to our firm name on the cover page of the Prospectus and under the heading “Interests of Experts”.

We confirm that we have read the Prospectus and that we have no reason to believe that there are any misrepresentations in the information contained in the Prospectus that:

- (a) are derived from our opinions referred to above; or
- (b) are within our knowledge as a result of the services that we performed to render such opinions.

Yours very truly,

(signed) “AIRD & BERLIS LLP”